Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million
Reuters2026/08/14 12:02- Replimune posted a GAAP net loss of USD 69.8 million for fiscal Q1 ended June 30, 2026, narrowing from USD 86.7 million a year earlier.
- R&D expense fell to USD 49.3 million from USD 57.8 million, on lower personnel and direct research costs across IGNYTE, ARTACUS, CERPASS.
- Selling, general and administrative costs dropped to USD 19 million from USD 32.6 million, including USD 4.1 million of stock-based compensation.
- Cash, cash equivalents and short-term investments totaled USD 195.3 million at quarter-end; August equity issuance added USD 141 million net proceeds.
- FDA granted accelerated approval to TUDRIQEV with nivolumab in advanced melanoma; U.S. launch expected within 60 days, IGNYTE-3 readout targeted 2030.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pons: $20.93 million has been paid to token creators over the past 47 days
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
Crypto prices
More
